Margit MacDougall

Discovery of (<i>S</i>)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1<i>H</i>-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, John Litchfield et al. · Journal of Medicinal Chemistry · 2011 · 115 citations · Full text

Life Sciences, Biochemistry, Pharmacology +14

Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes

Jianxin Yang, Margit MacDougall, Michael T. McDowell et al. · BMC Genomics · 2011 · 82 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Design of a Long Acting Peptide Functioning as Both a Glucagon-like Peptide-1 Receptor Agonist and a Glucagon Receptor Antagonist

Clark Q. Pan, Joanne Buxton, Stephanie Yung et al. · Journal of Biological Chemistry · 2006 · 70 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates et al. · MedChemComm · 2011 · 68 citations

Pharmacy, Biochemistry, Medicinal Chemistry +12

The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of Type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Meihua Tu, Kevin J. Filipski et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 44 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13